GEOGRAPHIC DISPARITY OF TREATMENT EFFECT IN THE PLATO TRIAL: FACT OR ARTIFACT?  by Kaul, Sanjay & Diamond, George A.
E1100
JACC April 5, 2011
Volume 57, Issue 14
  MYOCARDIAL ISCHEMIA AND INFARCTION 
GEOGRAPHIC DISPARITY OF TREATMENT EFFECT IN THE PLATO TRIAL: FACT OR ARTIFACT?
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Tuesday, April 05, 2011, 9:30 a.m.-10:45 a.m.
Session Title: Unstable Ischemic Syndrome -- Clinical: Randomized Trials and Registries
Abstract Category: 2. Unstable Ischemic Syndrome—Clinical
Session-Poster Board Number: 1139-310
Authors: Sanjay Kaul, George A. Diamond, Cedars-Sinai Medical Center, Los Angeles, CA
Background and Objective: The PLATO trial demonstrated substantial benefits for ticagrelor (T) over clopidogrel in a broad ACS population. 
However, US patients exhibited no benefit compared with non US patients (not a prespecified subgroup analysis). We sought to determine the 
validity of this surprising observation.
Methods:  Results for benefit (CV death, MI or stroke) and safety (total major or minor bleeding) were stratified according to geography (US vs. 
non US); and to low-dose (<100mg) aspirin (ASA), more common among non US pts, or high-dose (>100mg) ASA, more common among US pts. 
Treatment interaction relative to geography and ASA dose was determined before and after Bonferroni adjustment for 31 prespecified subgroup 
analyses.
Results (Table): T was associated with a significant 19% benefit in non US pts and a nonsignificant 27% hazard in US pts (interaction p=0.24). T 
was associated with a 23% benefit with low-dose compared with an 18% hazard with high-dose ASA (interaction p=0.03). No treatment interaction 
by geography or ASA dose was observed for bleeding risk.
Conclusion: Given the post hoc and qualitative nature of interaction, lack of biological plausibility (PK/PD and bleeding data not congruent) and 
absence of significant interaction when adjusted for multiple comparisons, the observed geographic disparity is likely to be spurious. Even when 
multiple subgroup analyses are prespecified, clinical and regulatory decisions should not be based on unadjusted analyses. 
Endpoint
US Non US P
interaction
Ticagrelor
n/N (%)
Clopidogrel
n/N (%)
Ticagrelor
n/N (%)
Clopidogrel
n/N (%)
CVD, MI,
Stroke
84/707
(11.9%)
67/706
(9.5% )
780/8626
(9.0%)
947/8585
(11.0%)
0.009
(0.24)*HR 1.27 (0.92-1.75) HR 0.81 (0.74, 0.90)
Total
major or
minor
bleeding
101/682
(14.8%)
76/675
(13.6%)
1238/8553
(14.5%)
1123/8511
(13.2% )
0.95
HR 1.09 (0.84-1.41) HR 1.10 (1.02-1.18)
Endpoint
ASA <100mg ASA >100mg P
interaction
Ticagrelor
n/N (%)
Clopidogrel
n/N (%)
Ticagrelor
n/N (%)
Clopidogrel
n/N (%)
CVD, MI,
Stroke
565/7733
(7.3%)
723/7706
(9.4% )
132/989
(13.3%)
115/1019
(11.3%)
0.001
(0.03)*HR 0.77 (0.69-0.86) HR 1.18 (0.94-1.49)
Total
major or
minor
bleeding
46/464
(9.9%)
46/492
(9.3%)
834/8258
(10.1%)
804/8233
(9.8% )
0.89
HR 1.06 (0.72-1.56) HR 1.03 (0.94-1.13)
*Adjusted analyses
